Trevi Therapeutics
General Information
195 Church Street
14th Floor
New Haven, CT 06510
US
Listing Information
Category
Life Sciences Employers
Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.
Source: 1WalletHub, 2024. 2U.S. Census Bureau, ACS 1Y, 2023. 3WalletHub, 2024. 4Milken Institute, 2022. 5Defined as per capita GDP; U.S. Bureau of Economic Analysis, 2024; U.S. Census Bureau, 2024; AdvanceCT calculations.
